• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis announces additional key appointments
Share
News

ProAxsis announces additional key appointments

July 26, 2022
-
Posted by Jessica Robinson

As part of its continuing expansion, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce further key appointments within its Northern Ireland team. 

Dr Louise Ryan Murphy joins the company as Head of Business Operations.  Louise brings a wealth of operational experience to ProAxsis, having previously held roles at Abbott Diagnostics, Horizon Discovery and PredictImmune with a focus on IVD medical devices. In her new role, she will be responsible for overseeing all in-house product development and clinical services projects as well as product manufacture and quality assurance activities.

Louise Ryan Murphy, newly appointed Head of Business Operations at ProAxsis, added: “I am delighted to be joining ProAxsis at such an exciting period of expansion and growth for the company.  I have been very impressed with the in-house talent and what they have achieved to date. I look forward to working with the team as we continue to expand and streamline operations, and to contributing significantly to the future success of the company.”

In addition, the company welcomes three new members of its R&D team – Ashleigh Kennedy, who returns to us after four years having previously completed a placement year at ProAxsis, Niall McDonagh and Matthew McCaffrey.  Ashleigh was most recently working at Almac, whilst Niall joins us from Randox.  Matthew also previously completed a placement year with the company and re-joins the company from Queen’s University Belfast.

Dr David Ribeiro, CEO of ProAxsis, commented: “We’re thrilled to have enticed someone of Louise’s calibre and experience to relocate back to Northern Ireland and become part of the World-leading diagnostics community here.  We’re also delighted to further expand our R&D team via the additions of Ashleigh, Niall and Matthew.”

Due to the growing nature of the company, we continue to look for high-quality candidates to join our team.  Any new opportunities will be posted on our website – www.proaxsis.com

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials. ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

July 26, 2022

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis provides update on commercialisation progress

November 21, 2017
-
Posted by Webmaster

Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in …

Read More
November 21, 2017
Posted by Webmaster
Announcements, Neutrophil Elastase Immunoassay, News

ProAxsis investing in R&D to create new diagnostic tests for chronic human diseases

July 27, 2020
-
Posted by David Ribeiro

Belfast based respiratory diagnostics company, ProAxsis is investing over £200,000 in R&D to enhance its novel ProteaseTag® …

Read More
July 27, 2020
Posted by David Ribeiro
Announcements, Neutrophil Elastase Immunoassay, News

ProAxsis Limited appoints distributor for key North America region

November 19, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory …

Read More
November 19, 2020
Posted by David Ribeiro
NEXT POST →
Belfast Telegraph Awards
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis announces additional key appointments - ProAxsis